Exiqon 2013 Revenues Rise 5 Percent Despite a 16 Percent Drop in Q4 | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon today reported a 5 percent increase year over year in its revenues for 2013, while revenues in its fourth quarter shrank 16 percent.

The Danish firm said that total revenues in 2013 grew to DKK123.6 million ($22.6 million) from DKK117.4 million in 2012. Life Sciences revenues rose 6 percent to DKK118.4 million from DKK111.3 million, offsetting a 15 percent drop in Diagnostics revenues to DKK5.2 million from DKK6.1 million, Exiqon said in its annual report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.